1. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial;Rugo;Ann Oncol,2018
2. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016
3. Pfizer Pharma GmbH. Dossier zur Nutzenbewertung gemäss § 35a SGB V: Palbociclib (Ibrance®); Modul 4A: Medizinischer Nutzen und medizinischer Zusatznutzen, Patientengruppen mit therapeutisch bedeutsamem Zusatznutzen. Stand: 22.11.2016. https://www.g-ba.de/downloads/92-975-1744/2016-11-22_Palbociclib_Modul4A.pdf (20 March 2018, date last accessed).
4. Institute for Quality and Efficiency in Health Care. Palbociclib (breast cancer) – benefit assessment according to §35a Social Code Book V. Published online 1 March 2017. https://www.iqwig.de/en/projects-results/projects/drug-assessment/a16-74-palbociclib-breast-cancer-benefit-assessment-according-to-35a-social-code-book-v.7749.html (20 March 2018, date last accessed).
5. FACIT. FACT-B Scoring & Materials Interpretation. http://www.facit.org/FACITOrg/Questionnaires (20 March 2018, date last accessed).